GlobeNewsWire
15 Jun 2026, 18:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Ethyreal Bio's lead candidate ETHY-001 demonstrated complete blockade of TSHR activation across all tested patient serum samples in preclinical trials. — Complete blockade in preclinical data is a high-signal indicator of potential efficacy for a lead asset, reducing early-stage technical risk.
+0.60The company plans to initiate the first-in-human clinical trial for ETHY-001 in the second half of 2026. — Moving from preclinical to clinical stages is a major value-inflection point for biotech companies.
+0.40ETHY-001 showed a differentiated activity profile in TED models by fully suppressing both hyaluronan and interleukin-6 secretion, unlike IGF-1R antagonists. — Differentiation from existing mechanisms of action suggests a potential competitive advantage or 'best-in-class' status in the market.
+0.30Continue reading
6 related stories
Search tags
ETHY-001 exhibited sub-nanomolar binding affinity to TSHR with no off-target binding across 5,000 human membrane proteins. — High specificity and affinity reduce the likelihood of off-target toxicity, improving the safety profile for future trials.
+0.20Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
4h ago
